Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments

Roberta Rudà, Lorenzo Bello, Hugues Duffau, and Riccardo Soffietti

Department of Neuro-Oncology, University of Turin and San Giovanni Battista Hospital, Turin, Italy (R.R., R.S.); Department of Neurosurgery, University of Milan and Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano (MI), Italy (L.B.); Department of Neurosurgery, University of Montpellier and Gui de Chauliac Hospital, Montpellier, France (H.D.)

Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + CCNU + vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence regarding their superiority in terms of efficacy.

Keywords: antiepileptic drugs, chemotherapy, diffuse gliomas, epileptogenesis, glioneuronal tumors, radiotherapy, seizures, surgery.

Most patients with low-grade gliomas (LGGs) experience epileptic seizures as a presenting symptom.1–4 Clinically, tumor-related seizures manifest as simple or complex partial seizures with or without secondary generalization and, in more than 50% of cases, are pharmacoresistant. When uncontrolled, tumor-related epilepsy affects patients' quality of life, causes cognitive deterioration, and may result in significant morbidity.5,6 Preoperative seizures could reflect intrinsic glioma properties7 and are the most important factor associated with continued seizures after tumor surgery.8 Seizures and their sequelae can mimic tumor progression and prompt unwarranted interventions. A number of studies have suggested an association between epileptic seizures at disease onset and a favorable prognosis.9–11 The management of seizures represents an important part of the management of LGG4,12 and increasingly needs specific and multidisciplinary approaches.

Factors Predisposing to Seizures

Tumor location influences the risk for epilepsy.13 Tumors involving the frontal, temporal, and parietal lobes are more commonly associated with seizures than are occipital lesions. Infratentorial tumors rarely cause seizures. Intractable epilepsy is particularly frequent in tumors that involve the mesiotemporal and insular (paralimbic) structures.14,15 This is linked to the high epileptogenicity of the temporal and insular cortex. Cortical tumors have a higher incidence of associated epilepsy than noncortical deeper lesions regardless of the involved lobe.15,16 Proximity to the Rolandic fissure and the central sulcus also increases seizure frequency.

The frequency of seizures differs widely according to tumor type. Glioneuronal tumors, such as gangliogliomas (GGs) and disembyroplastic neuroepithelial tumors (DNTs), are typically associated with a chronic pharmacoresistant epilepsy in up to 90%–100% of patients.17 They occur predominantly in children and young adults and in the temporal lobe. These tumors are designated by World Health Organization (WHO) classification18 as grade I tumors, thus most patients have a favorable outcome after surgical resection.
alone, with only rare cases of GGs that recur and/or undergo malignant transformation. Among DNTs, 2 histological variants, simple and complex, have been identified. Sometimes the differential diagnosis between these grade I tumors and the most common grade II gliomas is challenging due to sampling problems. The brain tissue adjacent to a GG or a DNT may frequently show an atypical cortical architecture due to a malformation of cortical development or cortical dysplasia; conversely, the presence of adjacent cortical maldevelopment is distinctly uncommon in grade II gliomas. Moreover, a dual pathology, such as hippocampal sclerosis in conjunction with the epileptogenic tumor, may occur. Other rare grade I gliomas, such as supratentorial pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and angiogenic gliomas, which prevail in children and young adults, frequently cause seizures.

Diffuse LGGs (WHO grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas) present seizures in 60%–88% of patients. Among LGGs, seizures are much less frequent (47% vs 85%) in patients ≥60 years compared with younger patients. Patients with oligodendrogliomas and oligoastrocytomas, which more often involve the cortex, are more prone to seizures than those with astrocytomas, which tend to be situated in the white matter. The rare protoplasmic astrocytoma, which is predominantly cortically based, can be linked to chronic epilepsy. Among grade II astrocytomas, a subtype characterized by long-term epilepsy, longer survival, and lower recurrence rate have been described. This subtype, called isomorphic astrocytoma, is characterized by low cellularity, lack of mitotic activity, highly differentiated astrocytic cells, absence of nuclear p53 accumulation, and expression of glial microtubule-associated protein 2 and cluster of differentiation molecule 34.

No correlation has been found between seizure activity and metabolic rate of the tumor measured by PET with methionine.

Unlike high-grade gliomas, LGGs presenting with seizures have been reported to be larger on MRI than those presenting with other neurological symptoms.

Mechanisms of Epileptogenesis

The pathogenesis of tumor-related seizures is multifactorial and still not fully understood. The mechanisms of epileptogenesis differ among tumor types.

Intrinsic epileptogenicity of glioneuronal tumors is supported by electrocorticography and surgical and immunocytochemical studies, suggesting the presence of a hyperexcitable neuronal component. The cells of these developmental tumors can overexpress neurotransmitter receptors and neuropeptides, compromising the balance between excitation and inhibition. The associated dysplastic disorganization of the adjacent cortex contributes to the mechanism of seizure generation. An extensive inflammatory reaction with accumulation of microglial cells in the perilesional areas has also been suggested.

Slow-growing tumors could produce an epileptogenic milieu by partial deafferentation of cortical regions, thus causing a denervation hypersensitivity.

Studies using magnetoencephalographic recordings have shown that functional connectivity and network topology are significantly altered in diffuse LGG cases compared low-frequency connectivity (in particular the theta band) is pathologically increased, and the normal “small-world network” configuration is altered, thus leading to a lower threshold for seizures. These differences not only implicate the area around the tumor, but involve brainwide networks and are related to cognitive deficits.

The role of changes in peritumoral tissue is being increasingly recognized. Neuronal density in the hippocampus of patients with mesial temporal lobe epilepsy and gliomas is normal; however, peritumoral cells may have an anomalous phenotype. Morphologic changes include aberrant migration with persistent neurons in the white matter, and pyramidal neurons with fewer inhibitory and more excitatory synapses. Intercellular connections between adjacent glial cells occur via connexin transmembrane gap junction proteins, and immunohistochemical studies have found altered expression of connexins in tumor cells and reactive astrocytes of the perilesional cortex of patients with LGGs and epilepsy.

Modern neuroimaging techniques have provided new evidence that the peritumoral microenvironment in brain tumors is substantially different from that of normal brain tissue: MR spectroscopy has demonstrated decreased levels of N-acetylaspartate, a marker of neuronal viability and function, in lesional epileptogenic cortex. Several alterations predispose to seizure generation. The tumor can mechanically compress the surrounding normal tissue because of mass effect, inducing ischemia, hypoxia, and acidosis, which in turn induce glial cell swelling and damage. A functional consequence of acidic pH is the deregulation of sodium and calcium influx across cell membranes. Further, the influence of pH on the activity of antiepileptic drugs (AEDs) is uncertain. Changes in ionic concentrations can also contribute to neuronal excitability, and a focal disruption of the blood–brain barrier leads to the development of a seizure focus.

Brain tumors and peritumoral tissue have an altered expression of neurotransmitters and their receptors. A greater concentration of glutamate, the major excitatory amino acid neurotransmitter in the brain, has been found in brain tumor samples from patients with active epilepsy. When invading the normal tissue, glioma cells could react to spatial constraints by releasing high levels of glutamate into the extracellular space, which induces seizures and later causes excitotoxic neuronal cell death, thereby facilitating invasion and migration. Ionotropic and metabotropic glutamate receptors have been shown to be overexpressed both in glioma cells and in peritumoral astrocytes. Activation of these receptors by glutamate could downregulate gamma-aminobutyric acid (GABA)–mediated inhibitory stimuli as a second mechanism of
epileptogenesis. Alterations in levels of GABA, the main inhibitory neurotransmitter, may also contribute to tumor-associated seizures, but it remains unclear whether decreased inhibition or new excitatory activity, together with altered receptor subtype expression, is responsible for neuronal hyperexcitability.35

Recent molecular–genetic findings have been described in glioneuronal tumors. A common role has been suggested for the phosphatidylinositol 3 kinase–mammalian target of rapamycin pathway in the pathogenesis of glioneuronal tumors, focal cortical dysplasias type IIb, and cortical tubers.45 Gene expression profiling of epilepsy-associated GGs has revealed alterations in the expression of genes involved in the immune system, synaptic transmission, and cell cycle control.48 Overall, it remains to be demonstrated that tumor-associated epilepsy and glioma growth have common genetic pathways.49

Regarding diffuse LGGs, susceptibility candidate genes associated with tumor-related seizures have not yet been identified. In this regard, it has been reported that LGGs without LOH19q were more likely to present with seizures of secondary generalized type than those with LOH19q, thus suggesting that candidate genes could be located on chromosome 19q.50

An actively discharging epileptic focus has the capability to induce a paroxysmal activity in areas of the brain distal to the original site and lead to a secondary epileptic focus, as occurs in cases of slow-growing tumors of the temporal lobe and long history of seizures. Both animal and human studies have demonstrated changes in synaptic plasticity and cerebral blood flow with prolonged epilepsy.51

Factors Influencing Preoperative Seizure Control

There is a lack of information on factors associated with preoperative seizure control in diffuse LGGs in the contemporary MRI era. In a recent large single-institution study, about half of patients had uncontrolled seizures.15 Associated with uncontrolled preoperative seizures were the presence of simple partial seizures, a longer duration from seizure onset, and temporal lobe involvement. Conversely, the presence of generalized seizures was associated with better seizure control.

Outcome after surgery

Surgery allows seizure control in a significant proportion of cases of diffuse LGGs, including pharmacoresistant epilepsy.52–58 A recent study performed a systematic review of the published literature involving 773 patients in order to identify factors associated with seizure outcome after surgery.39 Overall, gross total resection was the strongest predictor of seizure freedom at a minimum follow-up of 6 months postsurgery: 71% of patients were seizure free (Engel class I), whereas 29% continued to have seizures (Engel classes II–IV). Interestingly, in one of the major series,15 the benefit in terms of seizure control was maintained at 12 months, and conversely only 9% of patients had no improvement or worsened. These results have improved dramatically over time as a result of the increased use of preoperative neuroimaging modalities (functional MRI, diffusion tensor imaging), intraoperative brain mapping techniques, and awake surgery, which allow more aggressive resections while preserving normal eloquent areas. Thus, in the modern era, resection can be accomplished according to functional boundaries,60,61 and gross total resection means resection of abnormalities of fluid attenuated inversion recovery (FLAIR) on MRI. Unfortunately, as the majority of LGGs tend to grow close to or within eloquent areas,62 a total or near total resection is feasible in no more than 45% of patients.61 Recently the concept of supratotal resection (ie, removal of a margin around FLAIR abnormalities) for better seizure control has been put forward.63 In addition to gross total resection, preoperative seizure history may also predict outcome.59 Patients whose seizures were well controlled by AEDs preoperatively and whose seizures were ≤1 year in duration achieved better seizure control post surgery. The presence of nongeneralizing partial seizures was associated with poorer outcome. No significant difference in epilepsy outcome was found between temporal and extratemporal tumors and between adults and children. Second-line surgery can be useful for seizure control. In this setting, preoperative chemotherapy is being investigated.64,65

Regarding glioneuronal tumors, similarly to diffuse gliomas, gross total resection has emerged as the strongest predictor of seizure freedom. At a minimum follow-up of 6 months after surgery 80% of patients were seizure free (Engel class I), whereas 20% continued to have seizures (Engel classes II–IV).66 Moreover, early surgical intervention (<3 years from onset of seizures) was associated with improved seizure outcome.67 Other factors positively associated with seizure control were ≤1 year duration of epilepsy and the absence of secondarily generalized seizures preoperatively. Outcome did not differ significantly between patients with temporal lobe versus extratemporal tumors, histologic diagnosis of GG versus DNT, and medically controlled versus refractory seizures before surgery.66 Favorable seizure control has also been associated with factors such as younger age at surgery, presence of large nerve cells in the tumor specimen, and absence of postoperative epileptic discharges.19,68,69 Overall, among patients with temporal lobe epilepsy, long-term seizure control seems better in cases of glioneuronal tumors (94%) than of diffuse gliomas (79%) and cortical dysplasias (68%).70

A major issue related to surgery, especially in temporal and paralimbic tumors, is that the epileptogenic zone can include significant extratumoral cortical areas. Thus, 15%–20% of patients still suffer from refractory seizures after total tumor resection.55,77 In this setting the identification and removal of the epileptogenic zone beyond the tumor (ie, epilepsy surgery) could lead to an improved seizure outcome. Seizure outcome after lesionectomy versus lesionectomy + hippocampectomy,
cortical spread, or both in patients with medically intractable seizures has been compared in several series, and improved seizure control after epilepsy surgery has been found.14,59,66,71–74 An open question remains regarding the use of intraoperative electrocorticography to identify the epileptogenic areas in epilepsy surgery. A series of studies tried to address this issue, leading to inconclusive results.14,15,59,66,75–77 It is generally recognized that the cases in which electrocorticography was used were associated with more severe and refractory epilepsy.

**Role of Radiotherapy, Chemotherapy, and Targeted Therapy**

Limited data are available regarding the impact of radiotherapy on tumor-related seizures. Stereotactic interstitial irradiation improves seizure control in 40%–100% of unresectable LGGs,83,84 and this could be due to an increased benzodiazepine receptor density.79 Gamma-knife radiosurgery is active in mesiotemporal tumor-related epilepsy80 and in patients with gelastic or generalized seizures from hypothalamic hamartomas.81,82 Conventional radiotherapy has been reported to be effective in seizure control in 72%–100% of patients with medically intractable epilepsy and LGGs.83,84 Patients may become seizure free (27%–55%), and the median duration of seizure control is ~12 months but can be as long as 8 years. An indirect suggestion of the efficacy of radiotherapy on epileptic seizures comes from the EORTC (European Organisation for Research and Treatment of Cancer) 22845 phase III trial, which compared adjuvant postoperative radiotherapy versus observation in LGGs. At 1 year, 25% of patients who were irradiated had seizures, compared with 41% of patients who were not irradiated.85 After both interstitial and conventional radiotherapy, seizure reduction may begin early during radiotherapy and is not always associated with a tumor shrinkage on MRI. In fact, among patients who had a significant reduction of seizures after radiotherapy, ≤50% had stable disease on CT/MRI.83,84 Thus, in addition to a direct antitumor effect, ionizing radiation may decrease seizure activity by damaging epileptogenic neurons or inducing changes of the microenvironment in the peritumoral tissue.

The efficacy of chemotherapy with alkylating agents (procarbazine + CCNU + vincristine, temozolomide) in treating LGGs, either as salvage treatment after surgery and radiotherapy or as initial treatment after surgery in symptomatic/progressive patients, is well established.12 Seizure improvement has been obtained in 48%–100% of patients, with 20%–40% becoming seizure free.86–96 Clinical improvement is more frequent than objective response on MRI. The majority of patients have hyperintense lesions on T2/FLAIR images with ill-defined margins and display a minor response or stable disease. Decreased seizure frequency seems to be better correlated with decrease of uptake of methionine on PET, whereas no significant correlation between seizure response and 1p/19q codeletion has been reported so far.96

A significant decrease of epileptic seizures, in association with volume reduction on MRI, has been reported in subependymal giant-cell astrocytomas of tuberous sclerosis after treatment with the mTOR inhibitor everolimus.97,98

**Efficacy and Side Effects of Antiepileptic Drugs**

Studies regarding the impact of old AEDs (phenobarbital, phenytoin, carbamazepine) on tumor-related seizures are scarce. Overall, up to 70% of patients treated with these agents have recurrent seizures.99

In the last 10 years there have been an increased number of papers focusing on the efficacy and tolerability of new AEDs in patients with brain tumors;100–107 however, they are all small series, either retrospective or prospective, that group together different histologies (high-grade gliomas and LGGs, metastases, meningiomas, etc). No papers have evaluated this issue in LGGs only.

From a methodological point of view, when considering the efficacy of an AED, one should take into account the frequency of seizures, the phase of the disease (at diagnosis or at the time of progression), and the concomitant antineoplastic treatment (radiotherapy, chemotherapy) that may contribute to the control of seizures. Unfortunately in the published studies these issues have not been addressed adequately. Thus, lack of studies in homogeneous subgroups of patients probably explains the wide range of seizure response that has been reported.

In this review of the different series, we have tried to extrapolate the data regarding the efficacy of AEDs in LGGs. Table 1 summarizes the series in which these data are provided.

Most reports are on levetiracetam.102–104,107 This drug, employed either as an add-on or as monotherapy, has displayed a high rate of seizure response (75%–100%) with a good tolerance (mild drowsiness and dizziness in a few patients). Thus, levetiracetam may be a reasonable choice for the treatment of seizures in adults with brain tumors, particularly if concerns are raised about potential interactions with other medications, such as steroids or chemotherapeutic drugs.108 Two series have studied topiramate. Maschio et al.105 reported promising data in 13 cases of LGGs treated as add-on or monotherapy. The rate of response was 85% (with 7 of 13 patients seizure free), but 11 of 13 patients had received concomitant antineoplastic therapies (7 chemotherapy, 4 chemoradiotherapy), and the potential contribution of these treatments was not analyzed. In our series (R. Rudà, unpublished data), the setting was different: topiramate was employed as an add-on in patients with low-grade tumors and an active epilepsy with poor seizure control despite ≥1 AED. Good seizure control was obtained in 8% of patients only. Tiagabine was investigated as an add-on in 10 patients with LGG and drug-resistant partial epilepsy.101 A seizure
reduction > 50% was observed in 7 of 10 patients, with 3 patients becoming seizure free. Adverse events were seldom observed and did not lead to a discontinuation of the drug. More recently a small series was published on the use of lacosamide. In this prospective study, 14 patients were enrolled, including only 3 with LGGs. With a median follow-up of 6 months, the authors reported improved seizure control in all patients, with 2 of 3 being seizure free and 1 with a significant reduction of seizures. No side effects were reported. Overall, these studies suggest that side effects are less intense when newer, non-enzyme-inducing AEDs are administered in cases of brain tumors. Merrel et al. reported a retrospective comparative series of 76 cases of glioma treated with levetiracetam or phenytoin. There was no difference in seizure outcome between the phenytoin and levetiracetam groups, while patients treated with levetiracetam experienced fewer side effects and required fewer non-seizure-related dose adjustments than patients treated with phenytoin. Switching from phenytoin to levetiracetam monotherapy for seizure control following surgery of gliomas was reported to be safe and feasible in a randomized phase II study.

In conclusion, the available data on the efficacy and tolerability of AEDs in tumor-related epilepsy are scarce and heterogeneous due to the different histologies, the pathophysiology of seizures, the natural history of the tumor, and concomitant treatments. Needed are prospective trials focused on specific drugs in specific tumor categories. In current clinical practice, non-enzyme-inducing AEDs should be the first choice in the treatment of LGG due to a lesser incidence of side effects and lack of potential interactions with other drugs (especially steroids and chemotherapeutics). Seizure control together with a reduction of side effects should be the primary goals of therapy in cases of LGG where tumors are compatible with long survival.

**Interactions between Antiepileptic and Anticancer Agents**

Interactions have been reported between AEDs and chemotherapeutic drugs, based on shared cytochrome P450 drug metabolism. Potent inducers such as phenobarbital, phenytoin, primidone, and carbamazepine may significantly reduce serum levels of nitrosoureas, procarbazine, vincristine, cyclophosphamide, ifosfamide, paclitaxel, irinotecan, topotecan, 9-aminocampothecin, doxorubicin, teniposide, thiopeta, methotrexate, and busulfan. AED levels may also be affected by some chemotherapeutic agents, such as methotrexate, doxorubicin, adriamycin, and cisplatin, which decrease the serum levels of valproic acid, carbamazepine, and phenytoin. Demonstrating that temozolomide has minimal hepatic metabolism, one study documented no effect of temozolomide on levels of topiramate or oxcarbazepine in chronically treated patients.

Among targeted agents, bevacizumab, a monoclonal antibody against vascular endothelial growth factor that is under investigation in recurrent grade II gliomas...

---

**Table 1. Efficacy of novel AEDs in low-grade gliomas**

<table>
<thead>
<tr>
<th>Author</th>
<th>AED</th>
<th>Treatment Type</th>
<th>N. LGGs</th>
<th>Response Rate</th>
<th>Other Treatments</th>
<th>Median Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wagner, 2003</td>
<td>LEV</td>
<td>Add-on</td>
<td>8/26</td>
<td>37.5% (3/8) seizure free</td>
<td>N. R.</td>
<td>12.8 months</td>
</tr>
<tr>
<td>Rosati, 2010</td>
<td>LEV</td>
<td>Monotherapy</td>
<td>12/82</td>
<td>25% (2/8) unchanged</td>
<td>N. R.</td>
<td>13.1 months</td>
</tr>
<tr>
<td>Newton, 2006</td>
<td>LEV</td>
<td>Add-on and monotherapy</td>
<td>7/41</td>
<td>100% (12/12) seizure free</td>
<td>N. R.</td>
<td>13.5 months</td>
</tr>
<tr>
<td>Maschio, 2008</td>
<td>TPM</td>
<td>Add-on</td>
<td>13/47</td>
<td>5% (6/7) seizure free</td>
<td>N. R.</td>
<td>14 months</td>
</tr>
<tr>
<td>Ruda, 2012 unpublished</td>
<td>TPM</td>
<td>Add-on</td>
<td>24/50</td>
<td>8% (2/24) significant response</td>
<td>N. R.</td>
<td>6 months</td>
</tr>
<tr>
<td>Stiano, 2002</td>
<td>TGB</td>
<td>Add-on</td>
<td>10/11</td>
<td>0% (0/10) seizure free</td>
<td>1/3 TMZ + bevacizum</td>
<td>12 months</td>
</tr>
<tr>
<td>Maschio, 2011</td>
<td>LCM</td>
<td>Add-on</td>
<td>3/14</td>
<td>5% (2/3) seizure free</td>
<td>1/3 TMZ + temozolomide</td>
<td>12 months</td>
</tr>
</tbody>
</table>

Abbreviations: LEV, levetiracetam; TPM, topiramate; TGB, tiagabine; LCM, lacosamide; TMZ, temozolomide; N. R., not reported.
after standard treatments (EORTC 26091: TAVAREC), has a low potential for drug–drug interactions, whereas small tyrosine kinase inhibitor molecules (being investigated in clinical trials in malignant gliomas) such as imatinib, gefitinib, erlotinib, tipifarnib, and sorafenib are metabolized by the P450 system, thus leading to potential interactions with enzyme-inducing AEDs. Valproic acid has distinct enzyme-inhibiting properties and might reduce the metabolism of a second drug, thereby raising plasma concentrations and potentially increasing the bone marrow toxic effects of concomitant chemotherapeutic drugs such as nitrosoureas.

Also, metabolism of corticosteroids is highly sensitive to enzyme induction. Enzyme-inducing AEDs increase the metabolism of various steroids, including dexamethasone, possibly resulting in inadequate control of peritumoral edema.

Mechanisms of Resistance to Antiepileptic Drugs

The major cause of resistance of epilepsy to AEDs is overexpression of proteins belonging to the ATP-binding cassette transporter family (in particular P-glycoprotein [P-gp]), which actively transport a variety of lipophilic drugs out of the brain capillary endothelium at the level of the blood–brain barrier (the so-called multidrug-resistant proteins [MRPs]). An overexpression of these proteins has been reported in tumor cells of patients with glioma and in samples of brain tissue from patients with GG and could lead to diminished drug transport into the brain parenchyma. Moreover, the release of glutamate upregulates P-gp expression. A number of AEDs, including phenytoin, phenobarbital, carbamazepine, lamotrigine, and felbamate, are substrates for P-gp, making these drugs attractive in brain tumor–associated epilepsy. Valproic acid might even reduce the expression of MRP1 via its histone deacetylase-inhibiting effects.

AEDs may also fail to control seizures because of loss of receptor sensitivity.

The Problem of Prophylaxis

Antiepileptic therapy in cases of brain tumor is recommended after a first seizure. Two meta-analyses found no evidence to support prophylaxis with phenobarbital, phenytoin, or valproic acid in patients with no history of seizures. A recent Cochrane review pointed out several pitfalls of both meta-analyses and trials reviewed. The strength of evidence and recommendations are weakened by clinical heterogeneity among and within trials, misclassification of levels of evidence, and selection bias in the reporting of outcomes (especially adverse events). Hence, the authors prefer to state that the evidence for seizure prophylaxis is inconclusive, at best. Nonetheless, regarding implications for practice, they agree with the American Academy of Neurology subcommittee that recommended against routine use of AEDs as prophylaxis in cases of brain tumors and advised discontinuance of AEDs >1 week postsurgery when used as perioperative prophylaxis. However, many physicians still prescribe prophylactic AEDs, especially for prophylaxis of perioperative seizures.

It is unclear whether newer AEDs may have any benefit in preventing seizures. Only 2 retrospective trials are available. The first trial evaluated oxcarbazepine for prevention of early postoperative seizures, which occurred in <3% of patients, and found similar data to those reported for old drugs; moreover, oxcarbazepine was well tolerated with rapid titration. The second study compared levetiracetam with phenytoin after supratentorial neurosurgery and found that the incidence of early and late seizures was similar in both groups but that significantly fewer adverse events occurred with the use of levetiracetam, resulting in a higher retention rate after 1 year.

Conclusion

LGGs are the most epileptogenic brain tumors. Total or near total surgical resection predicts better seizure outcome for most low-grade histologies. This supports early operation not only based on oncological considerations, but also to avoid the risk of chronic epilepsy and optimize patient’s quality of life. However, no high-quality evidence, neither from randomized controlled trials nor from large registry studies, is available that addresses this question. Radiation and chemotherapy can be proposed when pharmacoresistant seizures still persist even if a true tumor progression is not evident. Newer AEDs seem to be better tolerated than the old drugs. Lastly, seizure control should always be a secondary endpoint in clinical trials in LGGs.

Conflict of interest statement. None declared.

References


